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ABSTRACT
Introduction: CHOICE (CHanges to treatment
and Outcomes in patients with type 2 diabetes
initiating InjeCtablE therapy; NCT00635492)
assessed, as its primary objective, the time to a
‘significant treatment change’ (defined within
this paper) after patients with type 2 diabetes
mellitus initiated their first injectable, glucose-
lowering therapy [exenatide twice daily (BID) or
insulin] in clinical practice in six European
countries and evaluated outcomes during the
study.
Methods: CHOICE was a 24-month, prospective,
noninterventional observational study. Patients
were invited to participate in CHOICE only after
their treating physician had made the clinical
decision to initiate first injectable therapy with
either exenatide BID or insulin. Clinical data were
collected at initiation of first injectable therapy
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Results: A total of 2,515 patients were recruited;
1,114 patients in the exenatide BID cohort and
1,274 patients in the insulin cohort were eligible
for the 24-month analysis. During the study,
42.2% and 36.0% of patients from each cohort,
respectively, had a significant treatment change.
By 24 months, improved mean glycated
hemoglobin (p\0.001 for both cohorts) and
reduced severity of several cardiovascular risk
factors were observed in both cohorts;
additionally, mean weight was reduced in the
exenatide BID cohort (p\0.001) and increased
in the insulin cohort (p\0.001). Hypoglycemia
was reported by 18.4% of the exenatide BID
cohort and 36.8% of the insulin cohort; 25.9% of
the exenatide BID cohort and 10.0% of the
insulin cohort had met the secondary endpoint
of glycated hemoglobin \7.0%, no weight gain,
and no hypoglycemia.
Conclusion: CHOICE provided data on
exenatide BID and insulin usage patterns and
24-month outcomes in clinical practice. On
average, improved glycemic control and
reduced severity of cardiovascular risk factors
were observed in both cohorts, and those in the
exenatide BID cohort also had mean weight loss.
Keywords: Diabetes mellitus; Exenatide;
Insulin; Injectable therapy; Type 2
INTRODUCTION
The management of type 2 diabetes mellitus
(T2DM) requires a multifactorial treatment
approach that addresses clinical and
psychosocial aspects of this chronic illness.
There are multiple therapeutic classes of oral
and injectable treatments available for T2DM.
Treatment should be selected and
individualized based on specific patient
requirements for glycemic control, and patient
preferences, characteristics, and susceptibilities
to side effects, including potential for weight
gain and hypoglycemia [1].
Glucagon-like peptide (GLP)-1 receptor
agonists are a relatively new class of
medications for T2DM. Randomized clinical
trials (RCTs) have shown that exenatide twice
daily (BID), the first approved GLP-1 receptor
agonist, provided glucose-lowering efficacy
similar to that of insulin glargine and biphasic
insulin aspart and that, in contrast with
insulins, it was associated with weight loss [2–
4]. Although RCTs provide the least biased
estimates of efficacy, data derived from a trial
setting have limited generalizability to routine
clinical practice, where treatment may be
initiated in patients dissimilar to those
enrolled in the clinical trial program, or it may
perform differently than in a controlled setting
and where modification of therapy is more
common [5, 6]. In addition, RCTs remove the
most important factor affecting the way in
which medical care is actually delivered:
doctors and patients acting as individuals with
differing beliefs, needs, and priorities. Well-
designed prospective observational studies in
clinical practice are therefore necessary to
provide a holistic understanding of treatment
[7, 8] and to enhance the evidence upon which
the management of T2DM is based [1]. To date,
limited information concerning the real-life use
of GLP-1 receptor agonists in Europe is available
and it is not clear how GLP-1 receptor agonists
compare with initial insulin therapy in real life.
For example, it has not been clear which
patients are prescribed these agents or initial
insulin treatment, how long GLP-1 receptor
agonists are taken, how patients who eventually
stop these agents or modify them by using
different combinations of antidiabetes
treatments are managed afterwards, and
finally, why some patients stop or modify
these therapies. Data are limited concerning
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the effectiveness, safety, and associated resource
use of both GLP-1 receptor agonists and insulin.
CHOICE (CHanges to treatment and
Outcomes in patients with type 2 diabetes
initiating InjeCtablE therapy; NCT00635492)
was a 24-month prospective observational
study conducted in multiple European
countries. It was designed to assess the time to
a significant treatment change after patients
initiated their first injectable, glucose-lowering
therapy in clinical practice and thereby evaluate
patterns of initial injectable therapy usage and
outcomes in clinical practice in patients with
T2DM. Significant treatment change was defined
as at least one of the following: discontinuation
of any exenatide BID/insulin initiated at
baseline; addition of a new medication (any
route of administration) for the treatment of
T2DM; a change in the number of times insulin
is administered per day; or substitution of a
human insulin for an analog insulin or vice versa
(not including switching between brands of the
same class/type of insulin). Details of the
characteristics of patients initiating the two
treatment strategies have been described [9].
This paper reports observed treatment changes
and clinical outcomes during the study.
PATIENTS AND METHODS
Design and Patients
CHOICE is a prospective, multinational,
noninterventional observational study that
recruited patients from six European countries
(Denmark, Belgium, France, Germany, Greece
and Sweden) between January 2008 and
October 2009. Eligible patients were aged
C18 years and initiating their first injectable
glucose-lowering therapy (with any type of
insulin or exenatide BID) for the treatment of
T2DM in routine clinical practice. Patients were
recruited through 322 investigators (mainly
secondary care sites). Patients were invited to
participate in CHOICE only after their treating
physician had made the clinical decision to
initiate either exenatide BID or insulin.
Therefore, treatment allocation was not
randomized and patients were treated as
determined by their physician and, at the time
of injectable treatment initiation, were
allocated to either the exenatide BID or
insulin cohort for analysis purposes. Although
exenatide once weekly and liraglutide have
more recently been approved, these GLP-1
receptor agonists were not available for
routine clinical use at the start of this study
and hence were not included for study. At study
entry, patients could be taking any oral
antidiabetes drugs (OADs).
The primary endpoint was the time from
starting the initial injectable regimen
(exenatide BID or insulin) to significant
treatment change. This endpoint was chosen
to meet payer needs for data on duration of
treatment with exenatide BID and to generate
similar data on insulin treatment.
At baseline (initiation of injectable therapy),
standard demographic and clinical data were
collected from each patient. At subsequent
visits (which occurred as part of routine
clinical practice: approximately 3, 6, 12, 18
and 24 months after baseline), changes to
injectable therapy, and the time of and reason
for the change, were recorded. Follow-up
clinical data collected during routine visits
included: glycated hemoglobin (HbA1c; when
available and taken from laboratory data
obtained as part of routine clinical practice);
body weight; waist circumference; body mass
index (BMI); fasting lipids; hypoglycemia;
gastrointestinal (GI) events (reported only
from the 4 weeks preceding each visit);
diabetes therapy and care; and concomitant
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medications. Other adverse event data were not
routinely collected as part of this study;
investigators were instructed to report as they
would in normal practice and as required by
applicable laws, regulations and practice.
Hypoglycemia was reported based on patient
recall using no specific definition, except for
severe hypoglycemia, which was defined as
requiring third-party assistance or a hospital
visit.
Patients gave written informed consent for
the use of their data and appropriate ethical
review board approval was obtained. For more
detail on the design of the CHOICE study, see
Matthaei et al. [9].
Analysis
Sample Size Justification
Monte Carlo simulation was used to calculate
sample size, and assumed patient dropout rates
of 10–15% per year and a median time to
significant treatment change of 9.0 months for
the exenatide BID cohort and 8.6 months for
the insulin cohort [10; data on file]. Based on
this, the study aimed to recruit a maximum of
800 patients per country/country group, with
approximately 60% initiating insulin and 40%
initiating exenatide BID. The insulin cohort was
to be larger than the exenatide BID cohort
because of the greater variability in the former
cohort (linked to use of different insulin
regimens).
Statistical Analysis
All patients who provided consent to release
information, fulfilled the study entry criteria
(‘eligible patients’), and had a case report form
summary page signed by an investigator were
included in the analysis. Analyses of the clinical
endpoints were conducted on the eligible
population in two ways: (1) according to the
cohort (insulin or exenatide BID) that they were
in at baseline (‘initiators analysis’); and (2)
using the groups of patients with no
significant treatment change (using the
original study definitions) at study end or at
the time of early discontinuation (this could be
at any time) from the study (‘persisters
analysis’). The persisters analysis was added
post hoc due to the observed incidence of
treatment changes. Early discontinuation
occurred when a patient was lost to follow-up,
withdrew from the study, or died at, or before,
the 24-month visit.
The primary objective was analyzed using
the initiators analysis group. Time to first
significant treatment change was estimated
using the Kaplan–Meier method for each
treatment cohort. If multiple types of change
occurred together, the changes were analyzed as
occurring in the order presented above. Reasons
for the change were summarized using
descriptive statistics.
Treatment changes occurring in the insulin
cohort were also categorized using an
alternative set of definitions that described the
intensity and efficacy of the new regimen
relative to the starter regimen. This definition
considered a significant treatment change to
arise if at least one of the following occurred:
switch (a change from one insulin regimen to
another regimen of similar complexity and
similar expected effectiveness); upgrade (a
change from one insulin regimen to another
of greater complexity or expected effectiveness);
downgrade (a change from one insulin regimen
to another of lesser complexity or expected
effectiveness); discontinuation (the initial
insulin regimen is stopped and no further
insulin is started within 30 days); initiation of
a GLP-1 receptor agonist; and ‘other’ (this
category included changes that could be
defined using the original criteria but which
288 Diabetes Ther (2013) 4:285–308
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did not fit within the new criteria); examples of
these categories are summarized in Appendix
Table 7.
Secondary objectives relating to clinical
outcomes data, medication use, and incidence
of GI events were reported for the initiators and
persisters analysis groups using descriptive
statistics for each visit as well as for the
change from baseline. Changes in weight and
HbA1c over time were explored using Mixed
Models for Repeated Measures analyses,
controlling for baseline weight/HbA1c,
propensity score, treatment visit, and the
treatment-by-visit interaction.
Propensity score analysis was used to
estimate the probability that a patient would
be assigned to a treatment group based on
baseline characteristics [11]. Scores were derived
from baseline data using logistic regression
(0.10 threshold for between-cohort
differences). Missing data were imputed with
the overall mean or median for continuous
variables, as well as the most frequent category
for categorical variables. Patients were matched
1:1 by country based on the propensity score
and optimal matching to identify matched
subsets from the two cohorts.
Cox regression models were applied within
each cohort to explore the association of
baseline characteristics with time to significant
treatment change and, post hoc, with the
clinically relevant composite secondary
endpoint of HbA1c \7.0%, no weight gain
(B1 kg), and no hypoglycemia [12].
Generalized estimating equation (GEE) models
were developed post hoc to explore factors
associated with switching treatment (from
exenatide BID to insulin, or from any insulin
to another insulin regimen of similar
complexity and similar expected effectiveness).
These models included baseline and time-
dependent covariates. Baseline variables
included microvascular and macrovascular
diagnoses, age, gender, and duration of
diabetes. Time-fluctuating variables included
GI symptoms, hypoglycemic episodes,
hospitalizations, and changes in BMI and
HbA1c. Statistical comparisons of endpoints
between the two cohorts were not conducted,
as the two treatment cohorts comprised
substantially different patient populations (see
Matthaei et al. [9]). However, comparative data
from a propensity score-derived matched
subgroup of the initiators population
(exenatide BID vs. insulin) are presented;
paired t tests were used to compare changes in
continuous variables and McNemar’s tests were
used to compare categorical variables between
the matched subgroups.
RESULTS
A total of 2,515 patients were recruited; 2,388
(95.0%) were eligible for the 24-month analysis;
1,114 in the exenatide BID cohort and 1,274 in
the insulin cohort (these patients were included
in the initiators analyses). Overall, 23.5% of the
eligible patients discontinued the study at or
before 24 months (reasons are shown in Fig. 1).
Demographic and Clinical Characteristics
Overall, patients in the exenatide BID cohort
tended to be younger and more obese, but had
better glycemic control and fewer diabetes
complications compared with the insulin
cohort (Table 1) [9].
Treatment Change
A total of 470 patients from the exenatide BID
cohort (42.2%) and 459 patients from the
insulin cohort (36.0%) had a significant
treatment change during the study. Therefore,
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644 patients from the exenatide BID cohort
(57.8%) and 815 patients from the insulin
cohort (64.0%) were included in the persisters
analyses.
In the exenatide BID group, the proportion
of enrolled patients experiencing treatment
change was highest (20.8%) in the first
6 months post initiation, and lower thereafter
(Fig. 2). Throughout the study, the proportions
of patients who had not had a significant
treatment change at 6, 12, 18 and 24 months
were 79.2%, 67.8%, 59.3% and 53.9%,
respectively. Almost three-fourths of the first
significant treatment changes were
discontinuations, with the remainder mainly
comprising the addition of oral antidiabetes
medications (Table 2).
In the insulin cohort, the proportions of
enrolled patients who had a significant
treatment change was also highest (22.1%) in
the first 6 months post initiation, and then
decreased during the remainder of the study
(Fig. 2). Throughout the study, the proportions
of patients who had not had significant
Fig. 1 Study disposition at 24 months. BID twice daily, DDP-IV dipeptidyl peptidase-IV, GLP-1 glucagon-like peptide-1,
OAD oral antidiabetes drug
290 Diabetes Ther (2013) 4:285–308
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treatment change at 6, 12, 18 and 24 months
were 77.9%, 70.6%, 64.9% and 60.6%,
respectively. The most common first
significant treatment change for insulin
patients was the addition of a new injectable
antidiabetes medication (45.3% of first
Table 1 Baseline clinical and demographic characteristics of patients with type 2 diabetes mellitus initiated on exenatide










Male [n (%)] 598 (53.7) 733 (57.5) 362 (56.2) 470 (57.7)
Age (years) 58.1 (10.1) 63.7 (10.9) 58.0 (10.1) 63.8 (11.0)
Weight (kg) 101.2 (21.7) 84.2 (17.6) 101.1 (21.0) 83.7 (17.4)
BMI (kg/m2) 35.3 (6.6) 29.7 (5.4) 35.1 (6.6) 29.5 (5.3)
Blood pressure (mmHg)
Systolic 137.7 (16.5) 137.4 (17.4) 138.1 (16.6) 137.5 (17.1)
Diastolic 81.7 (9.6) 80.2 (9.9) 82.0 (10.0) 80.3 (9.8)
Time since diabetes diagnosis (years) 8.2 (5.7) 9.8 (7.3) 8.1 (5.2) 9.9 (7.5)
HbA1c (%) 8.4 (1.4) 9.2 (1.9) 8.4 (1.4) 9.1 (1.9)
No. of OADs used [n (%)]
0 76 (6.8) 333 (26.1) 29 (4.5) 64 (7.9)
1 499 (44.8) 574 (45.1) 220 (34.2) 269 (33.0)
2 491 (44.1) 341 (26.8) 295 (45.8) 354 (43.4)
C3 48 (4.3) 26 (2.0) 100 (15.5) 128 (15.7)
Insulin regimen [n (%)]
Long-acting only NA 627 (49.2) NA 396 (48.6)
Short-acting only NA 147 (11.5) NA 57 (7.0)
Pre-mix NA 312 (24.5) NA 216 (26.5)
Basal-bolus NA 174 (13.7) NA 137 (16.8)
Other NA 14 (1.1) NA 9 (1.1)
Patients with C1 hypoglycemic event
(in past 3 months) [n (%)]a
59 (5.3) 56 (4.4) 33 (5.1) 28 (3.4)
Diabetes complications [n (%)]
C1 macrovascular complication 200 (18.0) 320 (25.1) 120 (18.6) 202 (24.8)
C1 microvascular complication 164 (14.7) 263 (20.6) 91 (14.1) 151 (18.5)
Continuous data are means (SD)
BID twice daily, BMI body mass index, HbA1c glycated hemoglobin, NA not applicable, OAD oral antidiabetes drug,
SD standard deviation
a Incidence is based on patient recall of events occurring during the past 3 months
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significant treatment changes; Table 2). When
changes in the insulin cohort were considered
using the alternative definition of treatment
change (i.e., describing the intensity and
efficacy of the new regimen relative to the
starter regimen), 0.6% added a GLP-1 receptor
agonist, 0.5% switched the type of insulin they
were using, 16.5% upgraded therapy, 0.2%
downgraded therapy, 7.7% discontinued
therapy, and 10.5% had ‘other’ changes. The
first significant treatment changes by insulin
type are presented in Fig. 3.
Throughout the 24-month observation
period, 393 patients (35.3%) in the exenatide
BID cohort and 155 patients (12.2%) in the
insulin cohort discontinued at least one
baseline injectable therapy. For 170 patients in
the exenatide BID cohort (15.3%) and
87 patients in the insulin cohort (6.8%) this
was because of inadequate response (Table 3).
Other reasons for discontinuation are
summarized in Table 3. Of the 393 patients
from the exenatide BID cohort, 10 patients
(2.5%) did not start anything else, 373 (94.9%)
started an (additional) OAD, 53 (13.5%) started
liraglutide, and 283 (72.0%) started insulin. Of
Table 2 First signiﬁcant treatment change occurring during the 24 months following initiation of exenatide BID or insulin





At least one signiﬁcant treatment change [n (%)] 470 (42.2) 459 (36.0)
First signiﬁcant treatment change [n (%)]a
Discontinuation of any injectable medication initiated at baseline 349 (31.3) 111 (8.7)
Addition of a new medication (any route of administration) for the treatment
of type 2 diabetes
121 (10.9) 267 (21.0)
Addition of a new oral medication 102 (9.2) 59 (4.6)
Addition of a new injectable medication 19 (1.7) 208 (16.3)
Change to the number of times insulin was administered per day NA 81 (6.4)
Substitution of a human insulin for an analog insulin or vice versa NA 0 (0)
BID twice daily, NA not applicable
a Where two categories of signiﬁcant treatment change occurred simultaneously, the categories were ordered:
(1) discontinuation of any injectable medication initiated at baseline; (2) addition of new medication; (3) change to the
number of times insulin was administered per day; (4) substitution of a human insulin for an analog insulin or vice versa
Fig. 2 Kaplan–Meier estimates for time until signiﬁcant
treatment change after initiation of injectable therapy with
exenatide BID or insulin. BID twice daily
292 Diabetes Ther (2013) 4:285–308
123
the 155 patients from the insulin cohort who
discontinued their baseline insulin, 18 patients
(11.6%) did not start anything else, 41 (26.5%)
switched a human insulin for an analog insulin,
or vice versa, 21 (13.5%) started an (additional)
OAD, 11 (7.1%) started liraglutide, and 106
(68.4%) started a new insulin. In addition,
18.2% of the exenatide BID cohort and 13.1%
of the insulin cohort discontinued their
baseline OADs. All antidiabetes medications
added or discontinued throughout the study
are presented in Table 4.
Cox proportional hazards models, performed
to investigate the impact of baseline medications
and patient clinical characteristics on time to
significant treatment changes, indicated that
there was nothing of clinical relevance in either
treatment cohort. In the exenatide BID cohort,
the final Cox proportional hazards model
identified the occurrence of GI symptoms
reported in the last 4 weeks prior to initiation of
injectable treatment to be statistically
significantly associated with a higher risk of
significant treatment change [hazard ratio (HR)
1.564; p = 0.007)]. In the insulin cohort, the final
Cox proportional hazards model identified the
following factors to be significantly associated
with a higher risk of significant treatment
change: higher baseline HbA1c (HR 1.121;
p\0.001), the occurrence of GI symptoms in
the last 4 weeks prior to initiation of injectable
treatment (HR 2.040; p\0.001), and the type of
insulin initiated. When compared with baseline
initiation of long-acting insulin only, patients
initiating basal-bolus insulin (HR 0.530;
p\0.001) or mixtures (HR 0.762; p = 0.026)
were less likely, whereas those initiating short-
acting insulin only were more likely (HR 2.373;
p\0.001) to have a significant treatment change.
The post hoc GEE model showed that in the
exenatide BID cohort, switching from exenatide
BID to insulin therapy was more likely among
patients who had an increase in BMI [no vs. yes,
odds ratio (OR) 0.464; p\0.001] or HbA1c (no vs.
yes, OR 0.731; p\0.001) over the duration of
treatment. There was no evidence for an
association between baseline characteristics and
this switch. The observed incidence of changing
the baseline insulin regimen (as per the primary
endpoint) was higher in patients who had an
increase in BMI (no vs. yes, OR 0.705; p\0.001),
increase in HbA1c (no vs. yes, OR 0.645;
p\0.0001), or who experienced hypoglycemia
(OR 0.691; p\0.001) over the duration of
treatment. Baseline microvascular diagnoses
(C1) were also associated with changes in
insulin regimen (no vs. yes, OR 0.656; p\0.01).
Clinical Outcomes and Adverse Events
Exenatide BID
Improvements were observed in HbA1c in the
exenatide BID cohort (Table 5). When
Fig. 3 First signiﬁcant treatment change (using the primary
deﬁnition) occurring during the 24 months following
initiation of insulin in patients with T2DM according to
baseline insulin regimen (the ‘other’ category comprised
combinations of a ‘mixture’ with either a ‘short-acting’ or
‘long-acting’ insulin). T2DM type 2 diabetes mellitus
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Table 4 Antidiabetes medications added or discontinued during the 24 months following initiation of exenatide BID or
insulin in patients with type 2 diabetes mellitus
















therapy added [n (%)]
298 (26.8) 257 (23.1) 325 (25.5) 298 (23.4)
Insulin
Long-acting 159 (14.3) 126 (11.3) 82 (6.4) 63 (4.9)
Intermediate-acting 61 (5.5) 45 (4.0) 62 (4.9) 55 (4.3)
Fast/short-acting 92 (8.3) 54 (4.8) 148 (11.6) 117 (9.2)
Mixtures 60 (5.4) 41 (3.7) 88 (6.9) 76 (6.0)
Exenatide 0 (0) 0 (0) 2 (0.2) 0 (0)
Liraglutide 53 (4.8) 34 (3.1) 15 (1.2) 8 (0.6)
Injectable antidiabetes therapy
discontinued [n (%)]
396 (35.5) NA 170 (13.3) NA
Insulin
Long-acting 18 (1.6) NA 67 (5.3) NA
Intermediate-acting 13 (1.2) NA 50 (3.9) NA
Fast-acting 6 (0.5) NA 40 (3.1) NA
Mixtures 7 (0.6) NA 51 (4.0) NA
Exenatide 393 (35.3) NA 0 (0) NA
Liraglutide 8 (0.7) NA 1 (0.1) NA
OADs added [n (%)] 180 (16.2) 158 (14.2) 88 (6.9) 65 (5.1)
Insulin
Alpha-glucosidase inhibitors 4 (0.4) 4 (0.4) 3 (0.2) 1 (0.1)
DPP-IV inhibitor 41 (3.7) 28 (2.5) 18 (1.4) 10 (0.8)
Metformin 32 (2.9) 30 (2.7) 23 (1.8) 18 (1.4)
SU 63 (5.7) 53 (4.8) 21 (1.6) 15 (1.2)
Meglitinide 21 (1.9) 14 (1.3) 17 (1.3) 15 (1.2)
TZD 29 (2.6) 24 (2.2) 9 (0.7) 5 (0.4)
Metformin and DPP-IV inhibitor 5 (0.4) 3 (0.2) 5 (0.4) 1 (0.1)
Metformin and SU 5 (0.4) 4 (0.4) 0 (0) 0 (0)
Metformin and TZD 10 (0.9) 6 (0.5) 2 (0.2) 2 (0.2)
Other 0 (0) 0 (0) 2 (0.2) 1 (0.1)
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controlling for baseline HbA1c, treatment and
visit, statistically significant improvements in
glycemic control were observed over the course
of the study in the exenatide BID initiator
population (p\0.001). Mean (standard
deviation, SD) HbA1c was 8.4 (1.4)% units at
baseline, 7.5 (1.2)% units at 3 months, and
remained between 7.3 (1.2)% units and
7.4 (1.2)% units at each further visit.
Improvements were also seen in mean values
of variables for a number of other cardiovascular
risk factors, including blood pressure and lipid
parameters (Table 5). In addition, mean weight
was significantly reduced in the exenatide BID
cohort by 24 months (Table 5; p\0.001).
Weight loss ([1.0 kg) was achieved by 62.2%
of initiators and 72.5% of persisters in the
exenatide BID cohort. In the initiators group,
mean (SD) baseline weight was 101.2 (21.8) kg;
at 3 months, this was 98.7 (21.7) kg and at each
further visit, mean weight remained between
97.7 (20.8) kg and 98.3 (21.3) kg. In the
exenatide BID persisters group, mean weight
decreased until month 18 and remained below
baseline levels for the remainder of the study.
Overall, 18.4% of patients who initiated
exenatide BID (15.7% of persisters)
experienced at least one episode of
hypoglycemia. The majority of episodes
occurred in patients receiving concomitant
sulfonylureas (Fig. 4). Severe hypoglycemia
(requiring third-party assistance or a hospital
Table 4 continued












6 weeks of ﬁrst
signiﬁcant
treatment change
OADs discontinued [n (%)] 358 (32.1) NA 545 (42.8) NA
Insulin
Alpha-glucosidase inhibitors 14 (1.3) NA 12 (0.9) NA
DPP-IV inhibitor 67 (6.0) NA 62 (4.9) NA
Metformin 60 (5.4) NA 140 (11.0) NA
SU 188 (16.9) NA 350 (27.5) NA
Meglitinide 48 (4.3) NA 48 (3.8) NA
TZD 75 (6.7) NA 78 (6.1) NA
TZD and SU 0 (0) NA 1 (0.1) NA
Metformin and SU 5 (0.4) NA 14 (1.1) NA
Metformin and TZD 36 (3.2) NA 21 (1.6) NA
Other 1 (0.1) NA 1 (0.1) NA
Patients could add/discontinue more than 1 treatment throughout the study
BID twice daily, DPP-IV dipeptidyl peptidase-IV, NA not applicable, OAD oral antidiabetes drug, SU sulfonylurea, TZD
thiazolidinedione
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visit) was experienced by 1.2% of exenatide BID
initiators (11 patients) and 1.1% of persisters
(6 patients). During the 3 months before the
baseline visit, the exenatide BID cohort had
experienced a mean (SD) of 0.4 (5.7)
hypoglycemic events. During the study,
patients in this cohort experienced a mean
(SD) of 1.3 (5.4) hypoglycemic events.
At 24 months, the proportion of patients
who met the composite endpoint of HbA1c
\7.0%, no weight gain (B1 kg change), and no
hypoglycemia was 25.9% and 32.2% in the
exenatide BID initiator and persister
populations, respectively. A shorter duration
of diabetes (p = 0.002) and lower HbA1c
(p\0.001) were associated with achievement
of this outcome in the exenatide BID cohort.
Overall, 30.8% of the exenatide BID cohort
experienced GI events; most commonly, nausea
(16.8% of patients). The number of patients
with GI events was higher in the first 6 months
(26.2% of patients with data) than in all
subsequent 6-month periods (\8% of patients
with data; events were reported from the
4 weeks prior to each visit only).
Insulin
Improvements were observed in HbA1c in the
insulin cohort (Table 5). When controlling for
baseline HbA1c, treatment and visit, statistically
significant improvements in glycemic control
were observed over the course of the study in
the insulin initiator population (p\0.001).
Mean (SD) HbA1c values were 9.2 (1.9)% units
at baseline, 7.5 (1.4)% units at 3 months, and
between 7.3 (1.0)% units and 7.3 (1.1)% units
for the remainder of the study period.
Improvements were also seen in mean values
of variables for a number of other cardiovascular
risk factors, including blood pressure and lipid
parameters (Table 5). However, mean weight
was significantly increased in the insulin cohort
(Table 5; p\0.001). Overall, 58.7% of insulin
initiators and 57.3% of persisters gained weight
([1.0 kg), with mean weight tending to increase
throughout the entire study for both initiators
and persisters. In the initiators group, mean
(SD) baseline weight was 84.2 (17.6) kg; at
3 months, mean weight was 84.9 (17.3) kg and
at each further visit, mean weight was between
85.6 (17.4) kg and 86.7 (17.8) kg.
Overall, 36.8% of patients who initiated
insulin (33.3% of persisters) experienced at
least one episode of hypoglycemia (Fig. 4).
Severe hypoglycemia (requiring third-party
assistance or a hospital visit) was experienced
by 8.4% of insulin initiators (76 patients) and
5.7% of persisters (34 patients). During the
3 months before the baseline visit, patients in
Fig. 4 Proportion of patients with T2DM reporting
hypoglycemia per 6-month period in the exenatide BID
(E) and insulin (I) cohorts, overall and according to use of
SUs; initiators analysis. SU use was deﬁned as any use of
SU during the study, irrespective of whether use was
interrupted or discontinued. BID twice daily, SU sulfo-
nylurea, T2DM type 2 diabetes mellitus
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the insulin cohort had experienced a mean (SD)
of 0.2 (2.3) hypoglycemic events. During the
study, patients in this cohort experienced a
mean (SD) of 3.7 (14.2) hypoglycemic events.
At 24 months, the proportion of patients
who met the clinically relevant composite
endpoint of HbA1c \7.0%, no weight gain
(B1 kg change), and no hypoglycemia was
10.0% and 11.8% in the insulin initiator and
persister populations, respectively. A shorter
duration of diabetes (p\0.001), lower HbA1c
(p\0.001), lower diastolic blood pressure
(p = 0.050), higher BMI (p = 0.002), the
absence of GI symptoms (p = 0.005), and
initial insulin regimen (mixtures versus basal
only; p = 0.004) were associated with
achievement of the composite endpoint.
Overall, 5.3% of patients in the insulin
cohort experienced GI events (most commonly
abdominal pain in 2.5% of patients).
Propensity-Matched Subgroup
Propensity matching of baseline patient and
disease characteristics identified 619 pairs of
patients who could be compared (51.8% of
the total sample). These patients had a mean
(SD) duration of diabetes of 9.1 (6.3) years
[9.0 (6.0) years for the exenatide BID group
and 9.2 (6.6) years for the insulin group]; other
baseline characteristics are summarized in
Table 6. In this propensity-matched subgroup,
patients in the exenatide BID group had
significantly greater mean (SD) weight loss
(p\0.0001) and a lower incidence of patient-
recalled hypoglycemia (p\0.0001) than the
insulin group during the study (Table 6).
However, there was no significant difference
between treatment groups regarding mean (SD)
change in HbA1c or in the percentages of
patients at 24 months with HbA1c \7.0% or
\6.5%. At 24 months, the proportion of
patients who met the composite endpoint of
HbA1c \7.0%, no weight gain (B1 kg change),
and no hypoglycemia was 26.9% in the
exenatide BID group and 11.0% in the insulin
group (p\0.0001, McNemar’s test) (post hoc
analysis).
DISCUSSION
CHOICE was a prospective observational study
designed to evaluate patterns of exenatide BID
and insulin usage and outcomes in clinical
practice in multiple European countries. In
this study, 42.2% of patients who initiated
exenatide BID and 36.0% who initiated insulin
had a significant treatment change during the
24 months after these treatments were started.
In another European study of insulin initiation
[13], rates of treatment change in the 24-month
period following insulin initiation were
2.9–19.4% (depending on insulin regimen). It
is unclear why the results of that study differed
from our findings. In CHOICE, patients in the
two treatment cohorts were substantially
different, with the exenatide BID cohort
tending to have a younger age, higher body
weight, BMI, waist circumference and diastolic
blood pressure, lower total and low-density
lipoprotein (LDL)-cholesterol levels, a shorter
time since diabetes diagnosis, and better
glycemic control at baseline than patients in
the insulin cohort [9]. Therefore, we were
unable to compare the clinical findings for the
total exenatide BID and insulin cohorts.
Time to significant treatment change was
chosen as the primary outcome of this study,
because it was anticipated that patients
prescribed exenatide BID would continue to
move through the available treatment
algorithms until insulin was initiated. A
combination of factors, including glycemic
control and tolerability, were believed to
influence treatment changes or
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Insulin (n5 619) p value
(change)
Baseline 24 months Baseline 24 months
Weight (kg) (n = 618) (n = 448) (n = 615) (n = 474)
93.2 (18.1) 90.8 (18.7) 91.8 (18.1) 93.8 (18.4) –
Change in weight (kg) (n = 448) (n = 472)
-2.8 (6.6) 1.5 (6.6) \0.0001
Blood pressure (mmHg)
Systolic (n = 615) (n = 425) (n = 612) (n = 442)
137.2 (16.7) 133.7 (14.5) 137.5 (16.5) 134.0 (15.0) –
Change in systolic (n = 422) (n = 437)
-3.6 (17.5) -3.1 (16.4) 0.3783
Diastolic (n = 615) (n = 425) (n = 612) (n = 442)
81.1 (9.3) 77.5 (9.6) 80.9 (10.0) 79.1 (8.8) –
Change in diastolic (n = 422) (n = 437)
-3.7 (11.2) -1.5 (10.6) 0.0017
HbA1c (%) (n = 600) (n = 452) (n = 604) (n = 473)
8.7 (1.5) 7.3 (1.1) 8.6 (1.5) 7.3 (1.1) –
Change in HbA1c (%) (n = 443) (n = 463)
-1.3 (1.5) -1.2 (1.5) 0.8473
HbA1c\7.0% [n (%)]
a (n = 600) (n = 411) (n = 604) (n = 420)
45 (7.5) 165 (40.1) 56 (9.3) 154 (36.7) –
HbA1c\6.5% [n (%)]
b (n = 600) (n = 421) (n = 604) (n = 441)
30 (5.0) 69 (16.4) 28 (4.6) 67 (15.2) –
Patients with C1 hypoglycemic event [n (%)]c (n = 619) (n = 590) (n = 619) (n = 597)
35 (5.7) 120 (20.3)* 30 (4.8) 199 (33.3) –
Patients with C1 GI symptoms, [n (%)]d (n = 618) (n = 590) (n = 619) (n = 597)
30 (4.9) 182 (30.8)* 30 (4.8) 35 (5.9) –
Lipids (mmol/L)
Total cholesterol (n = 561) (n = 336) (n = 551) (n = 381)
5.0 (1.0) 4.7 (1.0) 5.0 (1.1) 4.8 (1.0) –
Change in total cholesterol (n = 354) (n = 362)
-0.2 (1.0) -0.3 (1.1) 0.2066
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discontinuation. Clinicians and reimbursement
authorities in the European Union are therefore
interested in how long patients remain on
exenatide BID before intensifying or
discontinuing their therapy, and what
treatment changes are made. In addition,
guidelines recommend that patients maintain
glycemic control [1] because a lack of glycemic
control is associated with increased morbidity
[14], so the time taken to modify treatment in
response to poor control or unwanted adverse
effects for patients initiated on exenatide BID or
insulin is of interest. We found that the
proportion of enrolled patients with treatment
change in the exenatide BID group was highest
in the first 6 months of the study and then
decreased throughout the remainder of the
study. The majority of the first significant
treatment changes in this cohort were
discontinuations, with the remainder mainly
comprising the addition of oral antidiabetes
medications. The most frequent reasons for
treatment change were inadequate response
and adverse events. This is consistent with the
results of a recently published clinical trial [15].




Insulin (n5 619) p value
(change)
Baseline 24 months Baseline 24 months
HDL cholesterol (n = 542) (n = 358) (n = 527) (n = 361)
1.2 (0.3) 1.2 (0.3) 1.2 (0.3) 1.2 (0.4) –
Change in HDL (n = 339) (n = 338)
0.0 (0.2) 0.0 (0.3) 0.6591
LDL cholesterol (n = 531) (n = 346) (n = 514) (n = 357)
2.8 (0.9) 2.7 (0.9) 3.0 (1.0) 2.8 (0.9) –
Change in LDL (n = 327) (n = 330)
-0.1 (0.9) -0.3 (1.0) 0.4268
Triglycerides (n = 551) (n = 360) (n = 547) (n = 372)
2.4 (1.6) 1.9 (1.2) 2.4 (2.0) 1.9 (1.1) –
Change in triglycerides (n = 344) (n = 353)
-0.4 (1.4) -0.3 (1.5) 0.2045
Continuous data are means (SD); changes were compared between the 2 matched subgroups using paired t tests
BID twice daily, GI gastrointestinal, HbA1c glycated hemoglobin, HDL high-density lipoprotein, LDL low-density
lipoprotein, SD standard deviation
* p\0.0001 versus insulin, McNemar’s test
a Data from the subgroup of 555 patients in the exenatide BID group and 548 patients in the insulin group with HbA1c
C7.0% at baseline (144 and 128 patients, respectively, had missing data at 24 months)
b Data from the subgroup of 570 patients in the exenatide BID group and 576 patients in the insulin group with HbA1c
C6.5% at baseline (149 and 135 patients, respectively, had missing data at 24 months)
c Incidence is based on patient recall of events occurring: baseline = past 3 months; 24 months = past 24 months
d Patients with GI symptoms at baseline and those experiencing GI symptoms between baseline and 24 months
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increased BMI or HbA1c as factors associated
with a switch from exenatide BID to insulin
therapy.
In the insulin cohort, the proportions of
patients with significant treatment change were
also highest in the first 6 months of the study
and then decreased throughout the remainder
of the study. The most common first significant
treatment change for patients on insulin was
the addition of a new injectable antidiabetes
medication, with most patients requiring
upgraded therapy to a more intensive regimen.
When compared with baseline initiation of
long-acting insulin only, patients initiating
basal-bolus insulin or mixtures were less likely
to have significant treatment change, and those
initiating short-acting insulin only were more
likely to have significant treatment change
(Fig. 3). These observations are in line with
results of the 4T trial, which indicated that,
after 1 year, patients initially treated only with
long-acting insulin were more likely to require a
change in treatment (additional dose or
addition of a second insulin) than patients
initially receiving basal-bolus insulin [16] and,
after 3 years, patients initiated only on short-
acting or long-acting insulin required higher
insulin doses than those initiated on basal-bolus
insulin [17]. However, patients initiating only
short-acting insulin in the 4T trial were less
likely to require addition of another type of
insulin than patients initiated on long-acting
insulin after 1 year [16]. A switch from the
initial insulin regimen to another of similar
complexity and efficacy was more likely in
patients with at least one microvascular
diagnosis at baseline, and in patients with an
increase in BMI or HbA1c, or who experienced
hypoglycemia during treatment with their
baseline regimen. However, for both the
exenatide BID and insulin cohorts, treatment
change could not be directly linked with HbA1c
levels reported in this study as treatment
changes could have occurred between study
time-points, whereas HbA1c measurements were
recorded at study visits (i.e., not necessarily at
the time of treatment change).
Clinical findings from CHOICE appear
consistent when comparing findings from the
initiators population (which included patients
who had changed treatment), persisters
population (which comprised only patients
who remained on their initial injectable
therapy at study end or study discontinuation)
and on-drug population (which comprised all
patients from the initiators population up to
the time of any switch of treatment or
discontinuation of the initial injectable
therapy; data not shown). They are also in line
with findings from RCTs [18–20] and other
observational studies [21–24], although
comparability of the primary analyses (the
‘initiators’ analyses) with findings from other
studies is limited by the fact that patients could
be started on an alternative treatment while
remaining in CHOICE. The demographics and
characteristics of the patients from CHOICE
who were initiated on exenatide BID were
consistent with those of patients from the
Exenatide BID Observational Study (ExOS)
conducted in the United States [21, 22]. The
Association of British Clinical Diabetologists’
nationwide exenatide audit, which was
performed in the United Kingdom, included
patients who were broadly similar to our
population, except that their mean baseline
HbA1c was higher (9.47%) than in our study,
and 33.9% of patients in their study were also
receiving insulin at the time exenatide was
initiated [24]. In the US study, which was single-
arm and included patients initiated on
exenatide BID, irrespective of previous insulin
use, significant improvements were observed
after 12 months in HbA1c (-0.80%), weight
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(-2.4 kg), and BMI (-0.83 kg/m2; p B 0.0001 for
all) [21, 22]. The UK audit of patients recently
started on exenatide also revealed clinical
improvements after a median of 6 months of
exenatide therapy (the regimen was not
described), with reported decreases of 0.73%
for HbA1c, 5.9 kg for weight, and 2.2 kg/m
2 for
BMI (p\0.001 for all) [24]. Another study that
used a real-world setting to evaluate the
effectiveness of exenatide BID was the
retrospective claims database audit of Brixner
et al. [23]. Patients who were included in this
latter analysis were selected according to the
exenatide BID label [25] and had data for the
first 6 months after initiation of exenatide BID.
Clinical improvements in this study were again
consistent with our findings and those reported
in the other studies discussed here. However,
these studies have certain limitations in that all
were of relatively short duration (6 or
12 months) and were either single-arm or
retrospective in design. When compared with
prospective observational studies evaluating
initial use of insulin, 24-month results of the
INSTIGATE study showed that in three
European countries, 23.9% of patients changed
their insulin regimen (which was initiated at
the discretion of the treating physician) and
patients achieved similar reductions in HbA1c as
are reported in our study [26]. In CHOICE,
HbA1c was reduced by 1.0% units in the
exenatide BID cohort and 1.7% units in the
insulin cohort, although the change is likely
confounded by the higher baseline HbA1c in the
insulin cohort.
There has recently been a move toward
comparative effectiveness research and the
desire to compare therapies in clinical practice
[1, 27]. Although CHOICE was not designed to
do this, a matched subgroup of patients,
including approximately half the study
population, was identified using propensity
score data. Analyses conducted in these
patients did not demonstrate a difference
between the exenatide BID group and the
insulin group in mean changes in HbA1c, and
percentages of patients at 24 months with
HbA1c \7.0% or \6.5%. However, patients in
the exenatide BID-matched group had
significantly greater mean weight loss
(p\0.0001) and a lower incidence of patient-
recalled hypoglycemia (p\0.0001) than the
insulin-matched group during the study. These
findings are consistent with the results of RCTs
comparing GLP-1 receptor agonists and insulin
therapy [2–4, 28–30]. Although the incidence of
hypoglycemia relied on patient recall and was
not measured objectively in CHOICE, these
episodes may better reflect patient-relevant
hypoglycemia (i.e., those episodes that may
have caused anxiety or concern, or had an
impact on behavior or the self-management of
diabetes). In our study, 26.9% of patients in the
exenatide BID-matched subgroup achieved the
clinically relevant composite endpoint of HbA1c
\7.0%, no weight gain (B1 kg change), and no
hypoglycemia at 24 months. This compares
with 40% of liraglutide 1.8 mg and 32% of
liraglutide 1.2 mg recipients achieving this
endpoint according to the meta-analysis of
Zinman et al. [12]. However, these results for
liraglutide were achieved at 26 weeks in RCTs,
whereas our findings were obtained after a
considerably longer duration of treatment and
in a prospective, observational manner. These
findings, along with the requirement for
glucose monitoring and limited flexibility in
lifestyle to avoid hypoglycemia with insulin,
support the preferential use of GLP-1 receptor
agonists over insulin in selected patients, such
as those requiring weight loss or who are at risk
of hypoglycemia, as is recommended [1].
Prospective observational studies have
certain limitations, including the unknown
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magnitude of observer effects, the potential for
investigators to be influenced by the scrutiny
that occurs during a prospective study, and the
potential for selection bias. The inclusion of two
treatment cohorts is anticipated to have helped
reduce prescribing bias, as is the fact that
patients were invited to participate in our
study only after the clinical decision had been
made to initiate exenatide BID or insulin. This
inclusion criterion also avoided several
additional problems identified with some
observational studies, such as their propensity
to change the prescribing habits of the
participating physicians [31, 32].
Although the sample was designed to be
representative, recruitment targets were
prespecified, sample sizes were small in some
countries, the ratio of exenatide BID to insulin
patients varied between countries, and patients
were mostly recruited in secondary care centers.
The CHOICE study has provided the first
available data on the use of exenatide BID in
routine clinical practice across Europe. It is
likely that treatment patterns have changed
since this study was conducted. Additional GLP-
1 receptor agonist therapies are now available
(exenatide once weekly and liraglutide, for
instance) and in March 2012, exenatide BID
received EU approval as adjunctive therapy in
adult patients with T2DM who have not
achieved adequate glycemic control with basal
insulin, with or without metformin and/or
pioglitazone [33]. The latter was not an
approved indication for exenatide BID for the
duration of CHOICE, and only two patients
from the insulin cohort were initiated on this
agent during the study. However, we expect
that this new indication for exenatide BID may
have a substantial impact on prescribing trends
for patients with T2DM, as UK-based audits
have shown that between 30% and 40% of the
patients initiated on GLP-1 receptor agonists
before this indication was approved were also
receiving basal insulin concomitantly [24, 34].
CONCLUSION
In addition to estimating the time to first
significant treatment change and evaluating
reasons for the treatment change following
initiation of injectable therapy, CHOICE
provided data on exenatide BID usage patterns
and 24-month outcomes in clinical practice.
Results show that 42.2% of patients initiated on
exenatide BID and 36.0% of those initiated on
insulin as their first injectable glucose-lowering
therapy had a significant treatment change
during the first 24 months of therapy.
Nevertheless, patients in both treatment
cohorts achieved improved glycemic control
and a reduced severity of cardiovascular risk
factors, and those in the exenatide BID cohort
also achieved mean weight loss. These findings
for exenatide BID were consistent with results
reported from RCTs.
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APPENDIX
See Table 7.
Table 7 Examples of switch, upgrade, downgrade and discontinuation of insulin therapy according to the alternative
deﬁnition of treatment change
Baseline regimen New regimen Treatment change
Basal analog insulin NPH Switch
Basal analog insulin Prandial only, pre-mix Upgrade
NPH Basal analog insulin Switch
NPH Prandial only, pre-mix Upgrade
Pre-mix Basal/NPH only, prandial only, Downgrade
Pre-mix Basal-bolus Upgrade
Prandial analog insulin Basal/NPH only Downgrade
Prandial analog insulin Prandial human insulin Switch
Prandial human insulin Basal/NPH only Downgrade
Prandial human insulin Pre-mix Upgrade
Prandial analog insulin Pre-mix Upgrade
Prandial human insulin Prandial analog insulin Switch
Basal-bolus Basal/NPH only, prandial only, pre-mix Downgrade
Basal-bolus (human and/or analog) Basal-bolus (analog and/or human) Switch
Any regimen No regimen started within 30 days Discontinuation
Any regimen Same insulin regimen, oral antidiabetes drug Other
NPH neutral protamine hagedorn
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